Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients-Reference-Cited by-同舟云学术

Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients

Published:2020-08-31 Issue:4 Volume:112 Page:466-476
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ishiyama Ken,Nakao Shinji,Usuki Kensuke,Yonemura Yuji,Ikezoe Takayuki,Uchiyama Michihiro,Mori Yasuo,Fukuda Tetsuya,Okada Masaya,Fujiwara Shin-ichiro,Noji Hideyoshi,Rottinghaus Scott,Aguzzi Rasha,Yokosawa Jun,Nishimura Jun-Ichi,Kanakura Yuzuru,Okamoto Shinichiro

Funder

Alexion Pharmaceuticals, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-020-02934-6.pdf

Reference28 articles.

1. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. https://doi.org/10.1038/nrdp.2017.28.

2. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804–11. https://doi.org/10.1182/blood-2014-02-522128.

3. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207. https://doi.org/10.1097/01.md.0000126763.68170.46.